Cargando…
FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
Passive immunotherapy for Alzheimer disease has been tried for over 10 years without success. However, in 2021 and most recently in January 2023, the US Food and Drug Administration granted accelerated approval of 2 antibodies for this purpose, aducanumab and lecanemab. In both cases, the approval w...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317300/ https://www.ncbi.nlm.nih.gov/pubmed/37314733 http://dx.doi.org/10.1097/RLU.0000000000004710 |